title: Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells.
abstract: Macrophage inflammatory protein 1alpha (MIP-1alpha) is a chemokine that may act principally by preventing hemopoietic cells from entering G1, thereby attenuating the cytotoxic effects of cell cycle-specific chemotherapeutic agents. Here we examine the effect of MIP-1alpha on the sensitivity of human granulocyte-macrophage hemopoietic progenitor cells (granulocyte-macrophage colony-forming cells; GM-CFCs) with the cytotoxic effects of antitumor agents that act mainly via alkylation at the O6 position of guanine in DNA. Mononuclear cell preparations from human bone marrow were used in an in vitro GM-CFC colony-forming assay. The GM-CFC survival from individual patients displayed a range of sensitivities to the methylating agent temozolomide [(Tz) 20-55% survival at 10 microg/ml Tz]. However, in all 16 cases, MIP-1alpha (50 ng/ml) protected against GM-CFC killing: survival in the presence of MIP-1alpha ranged from 65-97% at 10 microg/ml Tz, with GM-CFCs being 1.5-4.5-fold more resistant than control cells from the same patient. The highest levels of protection were seen in the GM-CFCs with the highest sensitivity in the absence of MIP-1alpha. Similar degrees of protection were seen for the methylating agent streptozotocin, but no protection was detected for the chloroethylating agents carmustine or mitozolomide in the samples for which there was protection against the toxic effects of Tz. Whereas the mechanism of this effect remains to be established, the results may have potential immediate clinical application in the attenuation of hematological toxicity after administration of methylating antitumor agents.
authors.affiliation: Cancer Research Campaign Department of Medical Oncology, Manchester, United Kingdom. markclemons@sprint.ca
authors.forename: M
authors.initials: M
authors.lastname: Clemons
authors.forename: A
authors.initials: A
authors.lastname: Watson
authors.forename: A
authors.initials: A
authors.lastname: Howell
authors.forename: J
authors.initials: J
authors.lastname: Chang
authors.forename: C
authors.initials: C
authors.lastname: Heyworth
authors.forename: B
authors.initials: B
authors.lastname: Lord
authors.forename: N
authors.initials: N
authors.lastname: Testa
authors.forename: T M
authors.initials: TM
authors.lastname: Dexter
authors.forename: G
authors.initials: G
authors.lastname: Margison
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D003114:Colony-Forming Units Assay; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D019402:Macrophage Inflammatory Proteins / Q000494:pharmacology*; D013311:Streptozocin / Q000494:pharmacology; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D019402:Macrophage Inflammatory Proteins; D013311:Streptozocin; D003606:Dacarbazine; D000077204:Temozolomide